SynthesisMedicine2015
Diagnostic Value of Presepsin for Sepsis: A Systematic Review and Meta-Analysis.
Synthesis in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03584594 (Prepepsin, the Improvement of the Early Inflammatory Biomarkers Strategy for the Diagnostics of Sepsis in Critically Ill Patients), which is not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prepepsin, the Improvement of the Early Inflammatory Biomarkers Strategy for the Diagnostics of Sepsis in Critically Ill Patients
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Presepsin levels and COVID-19 severity: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Diagnostic efficacy of serum presepsin for postoperative infectious complications: a meta-analysis.Frontiers in immunology · 2023Pooled it
- Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis.BMC infectious diseases · 2019Pooled it
- Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis.PloS one · 2018Pooled it
- A Study Investigating Markers in PLeural Effusion (SIMPLE): a prospective and double-blind diagnostic study.BMJ open · 2019Trial
- Metabolic footprint of sepsis and septic shock: A narrative review.World journal of critical care medicine · 2026Review
- Presepsin as a Prognostic Biomarker for Short-Term Mortality in Adult Patients With Sepsis: A Systematic Review.Cureus · 2026Review
- The Global Impact of Sepsis: Epidemiology, Recognition, Management, and Health System Challenges.Epidemiologia (Basel, Switzerland) · 2026Review
- Utility of procalcitonin versus CRP in early sepsis detection.Bioinformation · 2026Article
- Sepsis in end-stage liver disease and acute-on-chronic liver failure: pathophysiology, diagnostic challenges, and pharmacological management.Frontiers in pharmacology · 2026Review
- Sepsis in liver failure patients: Diagnostic challenges and recent advancements.World journal of critical care medicine · 2025Review
- Elevated Serum Presepsin Identifies Herpes Simplex Virus-1 Reactivation in COVID-19 Patients.Viruses · 2025Article
- The Role of I-FABP, REG3α, sCD14-ST, and LBP as Indicators of GI Tract Injury in MODS Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Biomarkers of sepsis in burn injury: an update.Burns & trauma · 2025Review
- Biomarker Insights: Evaluation of Presepsin, Apelin, and Irisin Levels in Cutaneous Leishmaniasis.Diagnostics (Basel, Switzerland) · 2024Article
- Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Usefulness of presepsin as a prognostic indicator for patients with trauma in the emergency department in Korea: a retrospective study.Journal of trauma and injury · 2024Article
- Article
- The sCD14-ST predictive value in the development of adverse outcomes in operated colorectal cancer patients (diagnostic study).Annals of medicine and surgery (2012) · 2023Article
- Pleural Space Infections.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several individual studies have reported the diagnostic accuracy of presepsin (sCD14-ST) for sepsis, but the results are inconsistent.The present systematic review and meta-analysis pooled data to better ascertain the value of circulatory presepsin as a biomarker for sepsis.Studies published in English before November 7, 2014 and assessing the diagnostic accuracy of presepsin for sepsis were retrieved from medical databases.The quality of eligible studies was assessed using a revised Quality Assessment for Studies of Diagnostic Accuracy (QUADAS-2). The overall diagnostic accuracy of presepsin for sepsis was pooled according to a bivariate model. Publication bias was assessed using Deek funnel plot asymmetry test.Eleven studies satisfied the inclusion criteria. The overall diagnostic sensitivity of presepsin for sepsis was 0.83 (95% CI: 0.77-0.88), and specificity was 0.78 (95% CI: 0.72-0.83). The area under the summary receiver operating characteristic curve was 0.88 (95% CI: 0.84-0.90). The pretest probability of sepsis was 0.56 among all subjects. When presepsin was introduced as the diagnostic test for sepsis, the posttest probabilities were 0.81 for a positive result and 0.19 for a negative. The major design deficits of the included studies were lack of prespecified thresholds and patient selection bias. The publication bias was negative.Presepsin is an effective adjunct biomarker for the diagnosis of sepsis, but is insufficient to detect or rule out sepsis when used alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.